• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    6/13/23 9:07:03 AM ET
    $AIH
    $AXDX
    $BIOR
    $DERM
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AIH alert in real time by email

    Gainers

    • First Wave BioPharma (NASDAQ:FWBI) stock rose 136.5% to $2.7 during Tuesday's pre-market session. The company's market cap stands at $5.2 million.
    • YS Biopharma Co (NASDAQ:YS) shares rose 41.93% to $1.76. The market value of their outstanding shares is at $163.7 million.
    • iBio (AMEX:IBIO) stock rose 20.79% to $0.88. The market value of their outstanding shares is at $14.7 million.
    • SILO Pharma (NASDAQ:SILO) shares increased by 19.17% to $2.83. The company's market cap stands at $8.9 million.
    • PolarityTE (NASDAQ:PTE) stock increased by 13.94% to $0.23. The market value of their outstanding shares is at $1.6 million.
    • Journey Medical (NASDAQ:DERM) shares moved upwards by 13.77% to $1.9. The company's market cap stands at $34.4 million.

    Losers

    • Jin Medical International (NASDAQ:ZJYL) shares fell 20.1% to $10.55 during Tuesday's pre-market session. The company's market cap stands at $81.7 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares decreased by 17.98% to $5.11. The company's market cap stands at $60.5 million.
    • Landos Biopharma (NASDAQ:LABP) shares decreased by 12.7% to $3.37. The company's market cap stands at $10.5 million.
    • NextCure (NASDAQ:NXTC) shares declined by 11.38% to $1.48. The company's market cap stands at $41.1 million.
    • Aesthetic Medical Intl (NASDAQ:AIH) stock declined by 10.66% to $1.09. The market value of their outstanding shares is at $47.4 million.
    • Accelerate Diagnostics (NASDAQ:AXDX) stock decreased by 8.74% to $0.94. The company's market cap stands at $93.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $AXDX
    $BIOR
    $DERM

    CompanyDatePrice TargetRatingAnalyst
    NextCure Inc.
    $NXTC
    11/7/2025$18.00Neutral → Buy
    Ladenburg Thalmann
    iBio Inc.
    $IBIO
    10/21/2025$5.00Outperform
    Oppenheimer
    iBio Inc.
    $IBIO
    10/17/2025$2.00Outperform
    Leerink Partners
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    Journey Medical Corporation
    $DERM
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Journey Medical Corporation
    $DERM
    6/28/2024$11.00Buy
    ROTH MKM
    iBio Inc.
    $IBIO
    5/28/2024$5.00Buy
    Chardan Capital Markets
    More analyst ratings

    $AIH
    $AXDX
    $BIOR
    $DERM
    SEC Filings

    View All

    iBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    2/27/26 4:49:58 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by iBio Inc.

    S-3 - iBio, Inc. (0001420720) (Filer)

    2/27/26 4:23:59 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silo Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Silo Pharma, Inc. (0001514183) (Filer)

    2/23/26 5:00:43 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AIH
    $AXDX
    $BIOR
    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iBio to Participate in Upcoming Investor Conferences

    SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, February 26, 2026Time: 2:00 p.m. ETLocation: VirtualA livestream of the event can be accessed here. Leerink Global Healthcare ConferencePresentation Date: Monday, March 9, 2026 Time: 4:20

    2/24/26 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silo Pharma Announces Share Buyback Program

    Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements.   The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as repo

    2/23/26 4:15:00 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

    SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD). The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," strengthens Silo's growing intellectual-proper

    2/18/26 8:28:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AIH
    $AXDX
    $BIOR
    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:22 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sr VP, Dev. & Mfg. Kundu Sourav

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:20 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President & CEO Richman Michael

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:18 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AXDX
    $BIOR
    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AIH
    $AXDX
    $BIOR
    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NextCure upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded NextCure from Neutral to Buy and set a new price target of $18.00

    11/7/25 8:06:56 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on iBio with a new price target

    Oppenheimer initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00

    10/21/25 7:20:34 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on iBio with a new price target

    Leerink Partners initiated coverage of iBio with a rating of Outperform and set a new price target of $2.00

    10/17/25 8:34:58 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AXDX
    $BIOR
    $DERM
    Financials

    Live finance-specific insights

    View All

    Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

    11/12/25 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

    SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the

    11/5/25 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

    Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was

    10/6/25 8:10:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AIH
    $AXDX
    $BIOR
    $DERM
    Leadership Updates

    Live Leadership Updates

    View All

    Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

    Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin

    8/5/25 8:32:00 AM ET
    $SILO
    Apparel
    Consumer Discretionary

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AXDX
    $BIOR
    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care